We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pluristem Therapeutics Inc | NASDAQ:PSTI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.00 | 0.99 | 1.05 | 0 | 01:00:00 |
From May 2019 to May 2024
Pluristem recently announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication, where treatment was found to reduce the incidence of revascularization, improve patients’ mobility and validate the design of the company’s ongoing multinational Phase III study in Critical Limb Ischemia.
The event will take place at the TASE on Sunday, June 17, 2018 at 9:30am Israel time.
Pluristem welcomes its partners, investors and friends to join the event.
Registration is required at: Investor.relations@pluristem.com.
Contact:
Karine Kleinhaus, MD, MPHDivisional VP, North America1-914-512-4109karinek@pluristem.com
Efrat KaduriHead of Investor and Public Relations972-74-7108600efratk@pluristem.com
1 Year Pluristem Therapeutics Chart |
1 Month Pluristem Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
